China’s Healthcare Innovation Push: What It Means for Medical Tourism
China is not yet known as a global medical tourism giant in the same way as Thailand, Turkey, South Korea, India or Mexico. But the country is building something different: a healthcare innovation ecosystem that could slowly open new doors for international patients, especially in advanced medicine, special-access therapies and high-tech medical services.
A recent CGTN report highlights how China’s healthcare transformation is being driven by three connected forces: biomedical innovation, long-term industrial planning and greater openness to international healthcare cooperation. The most important medical tourism example is the Boao Lecheng International Medical Tourism Pilot Zone in Hainan, China’s special medical zone for advanced treatments and imported medical technologies.
For the global medical tourism industry, the question is not simply whether China can attract more foreign patients. The bigger question is whether China can turn its growing biomedical strength into a trusted international healthcare destination.
China is building a healthcare innovation platform
China’s biomedicine sector is becoming more concentrated, more advanced and more globally relevant. According to CGTN, the country has developed three major biomedical innovation hubs: the Yangtze River Delta, the Beijing-Tianjin-Hebei region, and the Guangdong-Hong Kong-Macao Greater Bay Area. Together, these hubs account for more than 80% of China’s industry resources, R&D capacity and market share.
Shanghai’s Zhangjiang, often called the “Pharma Valley of China,” is one of the clearest examples. CGTN reports that Zhangjiang is home to more than 4,000 innovation-driven enterprises and 140,000 researchers, making it one of China’s most important pharmaceutical and biomedical innovation centers.
This matters for medical tourism because successful international healthcare destinations are not built only on hospitals. They are built on ecosystems: hospitals, pharmaceutical companies, research centers, device companies, regulators, universities, airports, hotels, interpreters and patient-service systems.
China is trying to build exactly that kind of ecosystem.
China is moving from follower to innovator
The CGTN report presents China’s healthcare rise as the result of long-term planning rather than short-term market growth. China’s Healthy China 2030 strategy and successive Five-Year Plans have helped align government priorities, scientific research and industry investment.
The numbers are significant. According to the report, China conducted more than 1,300 clinical studies in 2025, around twelve times the number from a decade earlier. China’s National Medical Products Administration also approved 76 innovative medicines in 2025, while the country’s biomedicine industry reached an estimated market value of 5 trillion yuan, or about $700 billion, representing around 22% of the global market.
For medical tourism, this creates a new type of opportunity.
Traditional medical tourism is often based on lower cost. Patients travel because treatment is cheaper, faster or more available than in their home country. China’s possible advantage may be different. It may be based on access to new therapies, advanced devices, clinical expertise, real-world evidence, integrated hospitals and special regulatory zones.
That is where Boao Lecheng becomes important.
Boao Lecheng: China’s special medical tourism zone
The Boao Lecheng International Medical Tourism Pilot Zone was established in 2013 in Hainan Province. It is China’s only special medical zone designed to give patients faster access to cutting-edge drugs, medical devices and healthcare services from around the world.
The zone allows certain hospitals and medical institutions to use medicines and devices that have already been approved overseas but have not yet entered the broader Chinese mainland market. This makes Lecheng one of China’s most important healthcare access experiments.
By the end of 2025, the zone had introduced more than 530 internationally approved drugs and medical devices that had not yet entered the broader Chinese market, benefiting more than 200,000 patients, according to figures cited by CGTN.
Demand is also rising quickly. During the first ten months of 2025, the number of patients using special medical products in the zone increased by 137% year on year, while medical tourism visits rose by more than 80%, according to local government data cited by CGTN.
Other Chinese state media reports give even more detailed Lecheng figures. Xinhua reported that in 2025, Lecheng recorded 865,300 medical tourism visits, up 109.18% from the previous year. It also reported that the zone had introduced more than 500 innovative medicines and medical devices approved overseas but not yet available domestically.
This is one of the most important developments in China’s medical tourism strategy. Lecheng is not a simple cosmetic surgery destination. It is trying to become a gateway for advanced medicine.
But “medical tourism visits” does not always mean foreign patients
There is an important caveat.
When China reports “medical tourism visits” in Boao Lecheng, those numbers do not necessarily mean foreign medical tourists. A large part of the volume appears to come from domestic Chinese patients traveling to Hainan for special-access treatments, health management, rehabilitation, screening and wellness services.
This distinction matters for international investors, facilitators and hospitals.
Lecheng’s total medical tourism traffic may be large, but its inbound foreign-patient base appears much smaller. A June 2026 PR Newswire release about Lecheng’s new international medical tourism service center stated that in 2025, the zone received nearly 10,000 inbound medical tourists from 14 countries and regions.
That number is still meaningful, but it is not the same as Thailand, Turkey or South Korea’s mass-market international patient volumes.
So the current reality is this: China’s medical tourism potential is large, but its international patient market is still developing.
What makes China’s model different?
China’s medical tourism model is not likely to copy Turkey, Thailand or South Korea directly.
Turkey is strong in hair transplantation, dentistry, plastic surgery, eye care and private hospital treatment. South Korea is powered by K-beauty, dermatology, plastic surgery and wellness. Thailand combines hospitals, tourism, wellness and hospitality. Mexico benefits from proximity to the United States, especially in dentistry and bariatric surgery.
China’s strongest opportunity may be more specialized.
Its competitive edge could come from:
- access to special-approved drugs and devices
- advanced oncology and rare-disease treatments
- regenerative medicine and cell therapies
- high-end diagnostics
- rehabilitation and longevity programs
- integration with Hainan’s tourism economy
- biomedical research and clinical trials
- partnerships with global pharmaceutical and device companies
Lecheng is already moving in this direction. Reports describe the zone as a place where patients can access selected overseas-approved therapies before they are widely available in mainland China. Xinhua also reported that the zone has developed medical tourism routes covering services such as chronic disease rehabilitation, traditional wellness therapies and early screening programs.
This gives China a different market position. It may not first become a destination for mass-market dental or cosmetic tourism. It may first become a destination for patients seeking access to treatments, devices or health programs that are hard to obtain elsewhere in the region.
China is also building international patient infrastructure
Medical tourism does not grow only because hospitals are good. It grows when the patient journey becomes easy.
This includes consultation, diagnosis review, visa guidance, translation, transportation, hospital admission, treatment coordination, payment, recovery, follow-up and aftercare.
Lecheng appears to understand this. In June 2026, the zone launched an international medical tourism service center designed to provide one-stop support for global patients, including consultations, referrals, recuperation and cultural tourism. The service center also includes foreign-language hotlines, visa consultation, cross-border referral support and a dedicated “Service Officer” system for international patients.
This is a smart move.
China’s medical system can be difficult for foreign patients to navigate. Language, payments, documentation, visas, hospital selection and trust all create barriers. A centralized service system can reduce friction and make the country more accessible to international patients.
If China wants to compete seriously in medical tourism, these patient-service systems will be just as important as the medicine itself.
The opportunity: high-value medical tourism
China’s biggest medical tourism opportunity is probably not low-cost care. In many categories, China may not be cheaper than Turkey, India, Thailand or Mexico. For Western patients, China may also feel culturally and logistically more difficult than competing destinations.
But China could compete in high-value medical tourism.
That means patients may travel not because China is the cheapest, but because China offers something they cannot easily access elsewhere.
Examples could include:
- advanced cancer therapies
- special-access imported medicines
- rare-disease treatments
- innovative medical devices
- AI-assisted diagnostics
- longevity and preventive medicine
- rehabilitation programs
- integrated traditional Chinese medicine and modern medicine packages
- clinical-trial-related access pathways
This is a different type of medical tourism. It is less about “cheap surgery” and more about “access to innovation.”
If China can build trust, transparency and patient-friendly international services, this could become a powerful niche.
The challenge: global trust and patient perception
China’s healthcare sector is advancing quickly, but international patient trust will not be automatic.
Patients considering medical travel need to understand:
- who the doctor is
- whether the hospital is internationally credible
- what treatment is legally available
- what the treatment costs
- what happens if complications occur
- whether follow-up is possible after returning home
- whether language support is reliable
- whether outcomes data is transparent
- whether the patient’s home doctor can coordinate with the Chinese hospital
For China, the challenge is not only medical capability. It is communication, transparency and international reputation.
Countries like Thailand, Turkey, South Korea and India already have many years of global patient marketing experience. China has world-class hospitals and rising biomedical capability, but it still needs to make the international patient journey easier to understand.
Lecheng’s new service center is a step in that direction, but the broader China medical tourism brand is still young.
China’s global health role is expanding
The CGTN report also frames China’s healthcare transformation as part of a wider global health strategy. In June 2026, China’s State Council Information Office released a white paper on global governance, reaffirming China’s role in global health affairs. According to the white paper cited by CGTN, China has signed health cooperation agreements with more than 160 countries and international organizations, dispatched more than 30,000 medical workers to 77 countries and regions, and provided treatment to more than 300 million patients through overseas medical cooperation.
This is relevant because medical tourism is not only about individual patients. It is also about diplomacy, hospital partnerships, training, technology transfer and cross-border healthcare cooperation.
China’s healthcare opening may therefore develop through multiple channels:
- inbound medical tourism
- overseas hospital partnerships
- international training programs
- pharmaceutical exports
- medical device cooperation
- public health diplomacy
- clinical research partnerships
For Medical Tourism Watch readers, the key point is that China’s medical tourism potential should not be judged only by today’s inbound patient numbers. It should be judged by the infrastructure China is building.
What this means for the global medical tourism market
China’s rise could change the competitive map of medical tourism, but not immediately.
In the short term, China will likely remain a specialized destination rather than a mainstream mass-market medical tourism hub. Its strongest opportunity is in Hainan’s Boao Lecheng zone, high-tech care, special-access therapies, wellness, rehabilitation and advanced medicine.
In the medium term, China could become more important for patients from Asia, the Middle East, Africa and countries with strong business or diplomatic ties to China.
In the long term, if China improves transparency, international communication, hospital branding and patient coordination, it could become a serious player in high-value global healthcare travel.
The market opportunity is real. But China must solve the same problem every medical tourism destination faces: patients need trust before they travel.
Conclusion
China’s healthcare advances are opening new doors to the world, but the country’s medical tourism future will likely look different from other destinations.
It will not be built only on cheap procedures. It will be built on biomedical innovation, special medical zones, advanced therapies, global partnerships and high-value healthcare access.
Boao Lecheng is the clearest example. With more than 500 special-access drugs and devices, over 200,000 patients benefiting from the zone, and more than 865,000 medical tourism visits in 2025, it is becoming a serious testing ground for China’s international healthcare ambitions.
But China still has work to do. International patient volume remains small compared with leading medical tourism destinations, and the country must improve trust, transparency, language support and aftercare systems.
If it succeeds, China may not become the next Turkey or Thailand. It may become something else: a high-tech medical tourism destination built around access to innovation.
